Arjun Ramani , Ryland Townsend , Edwin Rodriguez , James M. Haughian , Laura K. Stewart
{"title":"每日饮用大麻二酚和左旋茶氨酸饮料不会改变焦虑、疲劳、认知功能或自然杀伤细胞功能:针对健康年轻人的随机对照试验","authors":"Arjun Ramani , Ryland Townsend , Edwin Rodriguez , James M. Haughian , Laura K. Stewart","doi":"10.1016/j.bbii.2024.100045","DOIUrl":null,"url":null,"abstract":"<div><p>Cannabidiol (CBD), a non-psychotropic <em>Cannabis sativa</em> derivative, and L-theanine, a green tea derivative, are gaining attention as potential promotors of psychological and cognitive health. The purpose of this double-blind, randomized, placebo-controlled study was to determine whether eight-week, daily consumption of beverages containing CBD, along with L-theanine, would improve psychological health, cognitive function, serum brain-derived neurotrophic factor (BDNF) as well as innate immune cell quantity and function in young, healthy adults. A total of 102 healthy participants were randomly assigned to, and successfully completed, 8 weeks of one of four treatment arms: 1) 60 mg CBD plus L-theanine (CB60; n = 25); 2) 30 mg CBD plus L-theanine (CB30; n = 28); 3) vehicle containing only L-theanine (LTV; n = 24); and 4) a calorie-matched placebo (PLAC; n = 25). After 8 weeks, plasma cannabinoid metabolite concentrations were significantly increased (p < 0.001) in CB60 and CB30 groups. There were no significant changes in anxiety, fatigue, and cognition, or serum BDNF concentrations as a result of the intervention and no treatment-related changes in natural killer (NK) and NKT cell populations or function. ClinicalTrials.gov (NCT05189275).</p></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"5 ","pages":"Article 100045"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949834124000011/pdfft?md5=b4d3b8ed823a77e6ff4bc691035801ae&pid=1-s2.0-S2949834124000011-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Daily cannabidiol and L-theanine beverage consumption does not alter anxiety, fatigue, cognitive function, or natural killer cell function: A randomized, controlled trial in healthy, young adults\",\"authors\":\"Arjun Ramani , Ryland Townsend , Edwin Rodriguez , James M. Haughian , Laura K. Stewart\",\"doi\":\"10.1016/j.bbii.2024.100045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Cannabidiol (CBD), a non-psychotropic <em>Cannabis sativa</em> derivative, and L-theanine, a green tea derivative, are gaining attention as potential promotors of psychological and cognitive health. The purpose of this double-blind, randomized, placebo-controlled study was to determine whether eight-week, daily consumption of beverages containing CBD, along with L-theanine, would improve psychological health, cognitive function, serum brain-derived neurotrophic factor (BDNF) as well as innate immune cell quantity and function in young, healthy adults. A total of 102 healthy participants were randomly assigned to, and successfully completed, 8 weeks of one of four treatment arms: 1) 60 mg CBD plus L-theanine (CB60; n = 25); 2) 30 mg CBD plus L-theanine (CB30; n = 28); 3) vehicle containing only L-theanine (LTV; n = 24); and 4) a calorie-matched placebo (PLAC; n = 25). After 8 weeks, plasma cannabinoid metabolite concentrations were significantly increased (p < 0.001) in CB60 and CB30 groups. There were no significant changes in anxiety, fatigue, and cognition, or serum BDNF concentrations as a result of the intervention and no treatment-related changes in natural killer (NK) and NKT cell populations or function. ClinicalTrials.gov (NCT05189275).</p></div>\",\"PeriodicalId\":100197,\"journal\":{\"name\":\"Brain Behavior and Immunity Integrative\",\"volume\":\"5 \",\"pages\":\"Article 100045\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949834124000011/pdfft?md5=b4d3b8ed823a77e6ff4bc691035801ae&pid=1-s2.0-S2949834124000011-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain Behavior and Immunity Integrative\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949834124000011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Behavior and Immunity Integrative","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949834124000011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Daily cannabidiol and L-theanine beverage consumption does not alter anxiety, fatigue, cognitive function, or natural killer cell function: A randomized, controlled trial in healthy, young adults
Cannabidiol (CBD), a non-psychotropic Cannabis sativa derivative, and L-theanine, a green tea derivative, are gaining attention as potential promotors of psychological and cognitive health. The purpose of this double-blind, randomized, placebo-controlled study was to determine whether eight-week, daily consumption of beverages containing CBD, along with L-theanine, would improve psychological health, cognitive function, serum brain-derived neurotrophic factor (BDNF) as well as innate immune cell quantity and function in young, healthy adults. A total of 102 healthy participants were randomly assigned to, and successfully completed, 8 weeks of one of four treatment arms: 1) 60 mg CBD plus L-theanine (CB60; n = 25); 2) 30 mg CBD plus L-theanine (CB30; n = 28); 3) vehicle containing only L-theanine (LTV; n = 24); and 4) a calorie-matched placebo (PLAC; n = 25). After 8 weeks, plasma cannabinoid metabolite concentrations were significantly increased (p < 0.001) in CB60 and CB30 groups. There were no significant changes in anxiety, fatigue, and cognition, or serum BDNF concentrations as a result of the intervention and no treatment-related changes in natural killer (NK) and NKT cell populations or function. ClinicalTrials.gov (NCT05189275).